Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion protein [CTLA-4-Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1-positive glomerular disease.
Abatacept in B7-1-positive proteinuric kidney disease / C. Yu, A. Fornoni, A. Weins, S. Hakroush, D. Maiguel, J. Sageshima, L. Chen, G. Ciancio, M.H. Faridi, D. Behr, K.N. Campbell, J. Chang, H. Chen, J. Oh, C. Faul, M. Amin Arnaout, P. Fiorina, V. Gupta, A. Greka, G.W. Burke III, P. Mundel. - In: NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 369:25(2013), pp. 2416-2423.
Abatacept in B7-1-positive proteinuric kidney disease
P. Fiorina;
2013
Abstract
Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion protein [CTLA-4-Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize β1-integrin activation in podocytes and reduce proteinuria in patients with B7-1-positive glomerular disease.File | Dimensione | Formato | |
---|---|---|---|
nejmoa1304572.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
712.47 kB
Formato
Adobe PDF
|
712.47 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.